Board of Directors

JAMIESON BONDARENKO, CFA, CMT
CHAIRMAN OF THE BOARD

Jamieson Bondarenko is an active investor and provides strategic capital markets & corporate development advice to early-stage life sciences companies through his merchant capital company, JGRNT Capital Corp. Jamieson was most recently Principal, Managing Director, Equity Capital Markets at Eight Capital. His previous roles include Equity Capital Markets and Investment Banking positions at Dundee Capital Markets, Wellington West Capital Markets, and HSBC Securities.Jamieson is a CFA Charterholder and a Chartered Market Technician.

MR. VAUGHN C. EMBRO-PANTALONY,MBA, FCPA, FCMA, CDIR, ACC
DIRECTOR OF THE BOARD

Mr. Embro-Pantalony is chairman of the board of Soricimed Biopharma Inc., a private clinical-stage biopharma company developing targeted cancer therapies. He is also a director of Microbix Biosystems Inc., a leading manufacturer of viral and bacterial antigens and reagents for the global diagnostics industry, where he also served as president and chief executive officer from 2012 to 2017. | Show More
He has held other executive positions in life sciences with responsibility for finance, business development, strategic planning and information technology including vice president, finance, and chief financial officer of Novopharm Limited; vice president, information technology, and chief information officer of Bayer Inc.; vice president, finance, and administration of Bayer Healthcare; and general manager, nitrogen products, for Terra International (Canada) Ltd.
He received his bachelor’s degree from Wilfrid Laurier University and his master of business administration degree from University of Windsor. He is a Fellow Chartered Professional Accountant and a Chartered Director (C. Dir.) and is Audit Committee Certified (A.C.C.) through the Directors College, McMaster University. | show less

MARTIN E. SCHMIEG
DIRECTOR OF THE BOARD

Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, LLC., a private company based in Massachusetts. | Show More
As a hands-on leader, Mr. Schmieg’s early career focused on accounting and financial management responsibilities serving as Chief Financial Officer to privately held Cytometrics, Inc., Advanced Bionics Corporation and publicly traded Sirna Therapeutics, Inc. and Isolagen, Inc. With Cytometrics, he raised $55 million in four rounds of venture capital financing to bring the company’s Cytoscan® instrument to market. With Advanced Bionics, he was the financial architect of the company’s sale to Boston Scientific (BSX) for $4.2 billion. With Sirna Therapeutics and in collaboration with its venture owners, he co-developed the company’s strategic plan which led to the company’s acquisition by Merck & Co for $1.3 billion. In 2006, Mr. Schmieg assumed the position of Chief Executive Office of Freedom-2, Inc., a venture startup in novel dermatology applications. While at Freedom-2, Mr. Schmieg raised $14 million in venture capital and led the company in the development and market introduction of InfinitInk®, which was a Time Magazine “Invention of the Year” in 2008. In 2009, Mr. Schmieg reversed merged Freedom-2 into Nuvilex, Inc., now PharmaCyte, Inc. Since 2010, Mr. Schmieg has been providing strategic advisory services to the life sciences industry including engagements with the following companies: NeoStem, Inc. (now Caladrius Biosciences, Inc.), Beckman Coulter Genomics, Calimmune, Inc., Cryoport, Inc., Sapientia Pharmaceuticals, Inc. and Rokk3r Labs, LLC. Martin holds a BS from LaSalle University, Philadelphia, PA and is a certified public accountant.
| show less

REBECCA TAUB, MD
DIRECTOR OF THE BOARD

Rebecca Taub, M.D., currently serves as President, R&D, and director of the board for Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics, since 2016. She acted as chief executive officer and director of the board of privately-held Madrigal Pharmaceuticals, Inc., since inception through its merger with Synta Pharmaceuticals Corp. | Show More
Previously, Dr. Taub served as senior vice president, R&D, of VIA Pharmaceuticals, and as vice president, research, metabolic diseases, at Hoffmann-La Roche where she oversaw clinical development and drug discovery programs for a number of indications including the conduct of a series of Phase I and II proof of concept clinical trials. She led drug discovery including target identification, lead optimization and advancement of preclinical candidates into clinical development. She previously worked at Bristol-Myers Squibb Co. and DuPont Pharmaceuticals Company in a variety of positions. Prior to becoming a pharmaceutical executive, Dr. Taub was professor of genetics and medicine at the University of Pennsylvania. She has authored over 120 research articles, served as an assistant professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University, and was associate investigator with the Howard Hughes Medical Institute. She received her Doctor of Medicine degree from Yale University School of Medicine and bachelor’s degree from Yale College. | show less

WILLIAM V. WILLIAMS, MD, FRCP
PRESIDENT & CEO

Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams served as VP of Exploratory Development at Incyte Corporation from 2005 – 2016. There he facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant). | Show More
He was responsible for establishing proof-of-concept in several therapeutic areas, and has been involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization in multiple therapeutic areas including oncology. This includes Jakafi for myelofibrosis and polycythemia vera and baricitinib for rheumatoid arthritis. As Head of Experimental Medicine and VP of Clinical Pharmacology at GlaxoSmithKline, Dr. Williams evaluated several molecules in clinical studies in various therapeutic areas. He ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. He supported drug development programs with a wide range of clinical applications. The clinical pharmacology of lapatinib, an orally active drug for breast cancer and other solid tumors, was characterized under his supervision. He was involved in new or supplemental drug authorizations for a number of oncology drugs including Bexxar (lymphoma), Hycamtin (ovarian cancer), and Navelbine (non-small cell lung cancer) as well as ibandronate (Boniva) for osteoporosis. Dr. Williams served as Head of Rheumatology Research at the University of Pennsylvania, ran a major research program in receptor biology, including developing bioactive peptides that mimicked granulocyte-macrophage colony-stimulating factor (GM-CSF), a known stimulant of the immune system. He collaborated with David B. Weiner, Ph.D., a well-known leader in immuno-oncology and vaccine research, in the development of DNA vaccines and was able to bring novel DNA vaccines into the clinic for the treatment of cutaneous T cell lymphoma.Dr. Williams earned his BSc. in Chemistry and Biotechnology from Massachusetts Institute of Technology and Medical Doctorate from Tufts University School of Medicine. Following his residency at the Boston VA Medical Center, Dr. Williams completed fellowship training in Rheumatology and Cellular Immunology at the University of Missouri. He then joined the molecular immunology laboratory of Mark I. Greene, MD, PhD, FRCP, at the University of Pennsylvania, developed novel methods of bioactive peptide design, and collaborated in the study of the activation of the p185/Human epidermal growth factor receptor 2 (HER2) receptor. HER-2 is a protein which is known to promote the growth of cancer cells. Dr. Williams is the named author at over 130 peer-reviewed publications, over 15 patents and numerous Investigational New Drugs (INDs) and NDAs. | show less

CHARLES L. WISEMAN, MD, FACP
DIRECTOR OF THE BOARD, CO-FOUNDER

Dr. Wiseman brings more than 40 years of academic and clinical experience to BriaCell Therapeutics Corp. As Co-Founder of BriaCell, he is the inventor for most of the Company’s intellectual property and actively participates in its ongoing technology development. | Show More
During his career, Dr. Wiseman has managed numerous clinical development teams and programs, with a focus in oncology, tumor immunology, vaccine development, and genetics. He was previously the principal investigator for immunotherapy treatment protocols at the St. Vincent Cancer Treatment Center and the Los Angeles Oncologic Institute.As the former Director of the Breast Cancer Basic Research Laboratory at the University of Texas M.D. Anderson Hospital in the 1970s, Dr. Wiseman was one of the pioneers of the field of cancer vaccine therapeutics.Dr. Wiseman has served as Clinical Professor of Medicine at the Division of Medical Oncology, Keck-USC School of Medicine, and previously was Acting Chief of the Division of Oncology/Hematology at White Memorial Medical Center. Dr. Wiseman has been cited in US News Top Doctors yearly since 2002.Dr. Wiseman received his a B.S. at UCLA as Outstanding Student of Chemistry, and received his MD degree there also, serving as President of the Student American Medical Association.Dr. Wiseman has written in over 100 peer-reviewed publications and medical textbook chapters. | show less

Briacell Management Team

WILLIAM V.WILLIAMS

William V. Williams, MD, FRCP
President & CEO

Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams served as VP of Exploratory Development at Incyte Corporation from 2005 – 2016.

There he facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant). | Show More
He was responsible for establishing proof-of-concept in several therapeutic areas, and has been involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization in multiple therapeutic areas including oncology. This includes Jakafi for myelofibrosis and polycythemia vera and baricitinib for rheumatoid arthritis.As Head of Experimental Medicine and VP of Clinical Pharmacology at GlaxoSmithKline, Dr. Williams evaluated several molecules in clinical studies in various therapeutic areas. He ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. He supported drug development programs with a wide range of clinical applications. The clinical pharmacology of lapatinib, an orally active drug for breast cancer and other solid tumors, was characterized under his supervision. He was involved in new or supplemental drug authorizations for a number of oncology drugs including Bexxar (lymphoma), Hycamtin (ovarian cancer), and Navelbine (non-small cell lung cancer) as well as ibandronate (Boniva) for osteoporosis.Dr. Williams served as Head of Rheumatology Research at the University of Pennsylvania, ran a major research program in receptor biology, including developing bioactive peptides that mimicked granulocyte-macrophage colony-stimulating factor (GM-CSF), a known stimulant of the immune system. He collaborated with David B. Weiner, Ph.D., a well-known leader in immuno-oncology and vaccine research, in the development of DNA vaccines and was able to bring novel DNA vaccines into the clinic for the treatment of cutaneous T cell lymphoma.Dr. Williams earned his BSc. in Chemistry and Biotechnology from Massachusetts Institute of Technology and Medical Doctorate from Tufts University School of Medicine. Following his residency at the Boston VA Medical Center, Dr. Williams completed fellowship training in Rheumatology and Cellular Immunology at the University of Missouri. He then joined the molecular immunology laboratory of Mark I. Greene, MD, PhD, FRCP, at the University of Pennsylvania, developed novel methods of bioactive peptide design, and collaborated in the study of the activation of the p185/Human epidermal growth factor receptor 2 (HER2) receptor. HER-2 is a protein which is known to promote the growth of cancer cells. Dr. Williams is the named author at over 130 peer reviewed publications, over 15 patents and numerous Investigational New Drugs (INDs) and NDAs. | show less

GADI LEVIN, CA, MBA
CFO & CORPORATE SECRETARY

Mr. Gadi Levin has been appointed as BriaCell Therapeutics Corp.’s Chief Financial Officer in February 2016. Most recently, he acted as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes.Mr. Levin served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate (2008 to 2009 and 2010, respectively). | Show More Pior to that, Mr. Levin acted as Financial Consultant to various firms.Mr. Levin began his career at the accounting firm, Arthur Andersen, where he worked in the Cape Town, London and Tel Aviv offices for nine years. He has a Bachelor of Commerce degree in Accounting and Information Systems from the University of the Cape Town, South Africa, and a post graduate diploma in Accounting from the University of South Africa. He received his Chartered Accountant designation in South Africa and has an MBA from Bar Ilan University in Israel. | show less


FARRAH DEAN, MSC, MBA
MANAGER, CORPORATE DEVELOPMENT

Farrah serves as Manager, Corporate Development at BriaCell Therapeutics Corp. Her experience includes working in investor relations at CytRx Corporation, and CCG Investor Relations. Farrah’s prior experience include Senior Associate Analyst in Equity Research at Oppenheimer & Co., Rodman & Renshaw, and ThinkEquity LLC.In her prior roles, Farrah analyzed biotechnology companies from financial, clinical, regulatory and commercial perspectives. Farrah received her BSc, and MSc from University of Toronto, and her MBA in Economics and Finance from Wilfrid Laurier University.